A buyer outlets in a Kroger grocery retailer on July 15, 2022 in Houston, Texas.
Brandon Bell | Getty Images
Investors have cheered a brand new class of weight loss medicine for his or her means to assist folks shed undesirable kilos, however the findings of a latest ballot underscore the challenges sufferers face in the event that they stop remedy.
The survey by Deutsche Bank discovered that calorie consumption declines when a affected person takes a GLP-1 treatment like Novo Nordisk’s Ozempic or Wegovy. However, as soon as the treatment is stopped, the variety of calories a affected person consumes will rise once more — and in some instances, will likely be even greater than what she or he was consuming earlier than remedy started, the survey discovered.
The polling was performed in December, and concerned 600 U.S. shoppers, Deutsche Bank mentioned in a analysis observe. Seventy p.c of the members have been utilizing a GLP-1 drug when questioned, whereas the remaining 30% had stopped taking this sort of treatment. The funding financial institution performed the survey as a part of its makes an attempt to higher perceive the long-term implications of anti-obesity drugs, which additionally embrace Eli Lilly’s Zepbound, on the meals and beverage business.
The survey discovered that among the many sufferers nonetheless on treatment, about 30% mentioned they ate “rather less,” whereas 22% mentioned they ate a “loads much less.”
“Perhaps surprisingly, 17% of respondents acknowledged that they have been consuming loads more and 18% somewhat more,” the financial institution’s analysts wrote. “This meant {that a} web 18% of those that have been utilizing GLP-1 treatment have been consuming much less.”
“However, amongst those that have been now not taking GLP-1 this more than reversed with a web 30% stating that they have been now consuming more than they have been prior to utilizing GLP-1 treatment,” the report mentioned.
“We imagine that the survey conclusions again up our view that GLP-1 is just not a purpose in of itself to keep away from investing in Food and Beverage shares,” the analysts wrote within the observe.
A 12 months to neglect
Without a doubt, 2023 was a 12 months price forgetting for a lot of meals and beverage shares, with many underperforming the market. For these shares that managed to eke out a acquire in 2023, the upside probably got here late within the 12 months.
Many meals and beverage shares started falling in the summertime, as consciousness of GLP-1 drugs like Wegovy unfold. The transfer accelerated after the discharge of information from Novo Nordisk in August confirmed that the medicine may assist sufferers not solely lose weight but in addition improve their cardiovascular health. Investors began to fear that folks would broadly undertake the medicine and there can be all sorts of ripple effects, which began to be mirrored in inventory costs.
But within the midst of the market’s year-end rally, a recent batch of information additionally confirmed that sufferers who took Zepbound and stopped regained around half the weight they had lost whereas they have been on the remedy. That discovering helped among the affected shares to recuperate.
Kraft Heinz shares over the previous 12 months.
Shares of Mondelez, the maker of Oreos and Cadbury, gained 16% over the previous three months, which helped it tally an 8% acquire over the previous 12 months. Kraft Heinz shares posted a ten.2% loss over the previous 12 months, however has reaped a 19% acquire over the three-month interval. U.S.-traded shares of Nestle are up more than 5% over the previous three months, however the inventory has a 2% loss over the previous 12 months. Unilever shares comply with an identical sample. Shares of the Ben & Jerry’s proprietor are up almost 2% over the previous three months, however are down more than 3% over the previous 12 months.
Appetite comes roaring again
Deutsche Bank mentioned the impression of anti-obesity medicines on meals and beverage shares wants to assessed “within the context of all weight loss applications and the chance that GLP-1 cannibalises such applications, limiting the online impact on meals and beverage producers.”
Dr. Shantanu Gaur, founder and CEO of Allurion Technologies, mentioned the outcomes of the survey aren’t stunning. Allurion, which went public via SPAC in August, is creating a gastric balloon and habits modification applications to deal with weight problems.
“This is one thing that you’d count on,” he mentioned explaining that “urge for food can return with a vengeance” as soon as sufferers cease GLP-1 remedy. Bodies have a tendency to search out a “set level,” or a most popular weight mass the place they are going to return to with out intervention and habits modification.
Semaglutide, the energetic ingredient in Ozempic and Wegovy, acts like a pure hormone, glucagon-like peptide-1, or GLP-1, within the physique to management insulin ranges within the blood and suppress urge for food. Zepbound (tirzepatide) mimics GLP-1 in addition to a second incretin, glucose-dependent insulinotropic polypeptide, or GIP. Once these hormones are now not supplemented within the physique, starvation alerts will return.
The American Medical Association has mentioned that weight problems is a power situation, and Novo Nordisk and Eli Lilly count on sufferers who take incretin drugs will want to be on the medicine long run to management their weight. In this manner, incretin medicine are like drugs which can be taken for situations resembling hypertension and ldl cholesterol. Patients aren’t informed to cease taking these medicine as soon as their blood stress and levels of cholesterol fall to a wholesome vary. If they do, the readings are probably to spike once more.
But even with blood stress treatment, compliance could be a problem. Dr. Gaur mentioned about half of individuals on ldl cholesterol treatment will cease taking it after a 12 months. The charge of compliance is even decrease with anti-obesity drugs, he mentioned.
Meanwhile, Deutsche Bank mentioned it expects curiosity in weight loss applications may be peaking as proven by web search knowledge, and that tends to be a great time for buyers to maintain meals and beverage shares. Nestle and Unilever are the agency’s prime European picks, whereas Mondelez and Kraft rank amongst its favored U.S. staples names.
“The primary level is that utilization of GLP-1 medicine isn’t just a pure addition to the whole variety of folks on weight loss applications, it’s a part of the complete eco-system,” the report mentioned. “We suspect that most of the solutions given with regard to consumption can be comparable for these given by many individuals once they begin a weight loss program.”
Don’t miss these tales from CNBC PRO: